SCHEMBL973137

SCHEMBL973137

O=NN1CCN(c2ccc(Cl)cn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.54
DRD2 P14416 5/20 0.46
PANK3 Q9H999 1/20 0.46
KMT2A Q03164 2/20 0.46
DRD4 P21917 4/20 0.45
HTR1A P08908 2/20 0.45
HTR2A P28223 2/20 0.45
HTR2C P28335 2/20 0.45
HTR7 P34969 2/20 0.45
DRD3 P35462 2/20 0.45
TMEM97 Q5BJF2 2/20 0.45
SIGMAR1 Q99720 2/20 0.45
GPR119 Q8TDV5 1/20 0.45
AOC3 Q16853 1/20 0.43
OGA O60502 1/20 0.42
RAB9A P51151 1/20 0.42
ME2 P23368 1/20 0.41
ME1 P48163 1/20 0.41
ME3 Q16798 1/20 0.41
TRPV1 Q8NER1 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16695272 0.78 CNR2 (0.73) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL972745 0.77 CNR2 (0.54) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL6125262 0.77 KMT2A (0.58) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL29656785 0.77 CNR2 (0.76) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL4754484 0.77 GPR119 (0.54) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL16397570 0.75 PANK3 (0.57) CNR2DRD2PANK3DRD4HTR1A
SCHEMBL1447393 0.75 CNR2 (0.55) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL1998095 0.75 CNR2 (0.55) CNR2DRD2PANK3KMT2ADRD4
SCHEMBL2155271 0.74 GPR119 (0.59) CNR2PANK3KMT2AGPR119RAB9A
SCHEMBL18711280 0.74 PANK3 (0.60) CNR2PANK3AOC3ME2ME1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872006-B2 Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-01-18 US disclosed
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-02-19 US disclosed
EP-1951678-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-06 EP disclosed
WO-2007046550-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity CNR1, CNR2, OPRD1 CNR2 2/4885DRD2 4/4885PANK3 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.